Phase 1/2 Open-Label Trial Of Sutent (Sunitinib Malate) And Aromasin(Exemestane) In The First-Line Treatment Of Hormone Receptor-Positive Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 16 Sep 2010
At a glance
- Drugs Exemestane; Sunitinib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Jun 2009 Results were presented at ASCO 2009.
- 20 May 2009 Planned end date changed from 1 Oct 2011 to 1 Jul 2009 as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.